Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Adaptimmune Therapeutics PLC (ADAPY) vs Clovis Oncology, Inc. (CLVSQ)

Adaptimmune Therapeutics PLC and Clovis Oncology, Inc. are both Biotechnology companies. Adaptimmune Therapeutics PLC and Clovis Oncology, Inc. are of similar size ($14.6M and $14.2M). Clovis Oncology, Inc. grew revenue faster over the last twelve months: −14.8% against −54.0%. Clovis Oncology, Inc. has the higher net margin (−189.4% vs −262.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Clovis Oncology, Inc. leads on 11 and Adaptimmune Therapeutics PLC on 5.

Valuation

Metric ADAPY CLVSQ Biotechnology median
P/E n/m n/m 7.88
P/S 0.12 0.10 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.12 3.08 10.73
Earnings yield (2,166.67%) (2,033.33%) (28.84%)
Free cash flow yield (2,380.45%) (1,412.40%) (23.03%)

Profitability

Metric ADAPY CLVSQ Biotechnology median
Gross margin 94.81% 72.21% 65.16%
Operating margin (427.75%) (155.38%) 0.00%
Net margin (262.46%) (189.37%) 0.00%
Free cash flow margin (288.20%) (132.19%) 0.00%
Return on equity (1,349.52%) 78.31% (57.72%)
Return on assets 0.00% (58.94%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ADAPY CLVSQ Biotechnology median
Revenue growth (TTM) (53.99%) (14.78%) 5.64%
EPS growth (last fiscal year) 142.86% 47.72% —
Revenue growth, 5-year CAGR 8.40% 352.98% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADAPY CLVSQ Biotechnology median
Debt to equity (0.36) (1.09) 0.00
Current ratio 1.52 0.14 4.73
Net debt to EBITDA 0.47 (2.21) 0.96

Dividend

Metric ADAPY CLVSQ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ADAPY CLVSQ Biotechnology median
Market cap 14.55m 14.23m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack